Oncogenic ras and p53 Cooperate To Induce Cellular Senescence

REFERENCES

• Agarwal, M. L., A. Agarwal, W. R. Taylor, and G. R. Stark. 1995. p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc. Natl. Acad. Sci. USA 92: 8493–8497.
   PubMed Web of Science ®Google Scholar
• Chen, X., L. J. Ko, L. Jayaraman, and C. Prives. 1996. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev. 10: 2438–2451.
   PubMed Web of Science ®Google Scholar
• Cross, S. M., C. A. Sanchez, C. A. Morgan, M. K. Schimke, S. Ramel, R. L. Idzerda, W. H. Raskind, and B. J. Reid. 1995. A p53-dependent mouse spindle checkpoint. Science 267: 1353–1356.
   PubMed Web of Science ®Google Scholar
• Debbas, M., and E. White. 1993. Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Dev. 7: 546–554.
   PubMed Web of Science ®Google Scholar
• de Stanchina, E., M. E. McCurrach, F. Zindy, S. Y. Shieh, G. Ferbeyre, A. V. Samuelson, C. Prives, M. F. Roussel, C. J. Sherr, and S. W. Lowe. 1998. E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev. 12: 2434–2442.
   PubMed Web of Science ®Google Scholar
• Di Leonardo, A., S. P. Linke, K. Clarkin, and G. M. Wahl. 1994. DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev. 8: 2540–2551.
   PubMed Web of Science ®Google Scholar
• Dimri, G. P., X. Lee, G. Basile, M. Acosta, G. Scott, C. Roskelley, E. E. Medrano, M. Linskens, I. Rubelj, O. Pereira-Smith, M. Peacocke, and J. Campisi. 1995. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. USA 92: 9363–9367.
   PubMed Web of Science ®Google Scholar
• Ferbeyre, G., E. de Stanchina, E. Querido, N. Baptiste, C. Prives, and S. W. Lowe. 2000. PML is induced by oncogenic ras and promotes premature senescence. Genes Dev. 14: 2015–2027.
   PubMed Web of Science ®Google Scholar
• Fogal, V., M. Gostissa, P. Sandy, P. Zacchi, T. Sternsdorf, K. Jensen, P. P. Pandolfi, H. Will, C. Schneider, and G. Del Sal. 2000. Regulation of p53 activity in nuclear bodies by a specific PML isoform. EMBO J. 19: 6185–6195.
   PubMed Web of Science ®Google Scholar
• Gannon, J. V., and D. P. Lane. 1991. Protein synthesis required to anchor a mutant p53 protein which is temperature-sensitive for nuclear transport. Nature 349: 802–806.
   PubMedGoogle Scholar
• Giaccia, A. J., and M. B. Kastan. 1998. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev. 12: 2973–2983.
   PubMed Web of Science ®Google Scholar
• Ginsberg, D., F. Mechta, M. Yaniv, and M. Oren. 1991. Wild-type p53 can down-modulate the activity of various promoters. Proc. Natl. Acad. Sci. USA 88: 9979–9983.
   PubMed Web of Science ®Google Scholar
• Gostissa, M., A. Hengstermann, V. Fogal, P. Sandy, S. E. Schwarz, M. Scheffner, and G. Del Sal. 1999. Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1. EMBO J. 18: 6462–6471.
   PubMed Web of Science ®Google Scholar
• Graeber, T. G., C. Osmanian, T. Jacks, D. E. Housman, C. J. Koch, S. W. Lowe, and A. J. Giaccia. 1996. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379: 88–91.
   PubMed Web of Science ®Google Scholar
• Graeber, T. G., J. F. Peterson, M. Tsai, K. Monica, A. J. J. Fornace, and A. J. Giaccia. 1994. Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol. Cell. Biol. 14: 6264–6277.
   PubMed Web of Science ®Google Scholar
• Guo, A., P. Salomoni, J. Luo, A. Shih, S. Zhong, W. Gu, and P. Paolo Pandolfi. 2000. The function of PML in p53-dependent apoptosis. Nat. Cell Biol. 2: 730–736.
   PubMed Web of Science ®Google Scholar
• Hainaut, P., and J. Milner. 1993. Redox modulation of p53 conformation and sequence-specific DNA binding in vitro. Cancer Res. 53: 4469–4473.
   PubMed Web of Science ®Google Scholar
• Hannon, G. J., P. Sun, A. Carnero, L. Y. Xie, R. Maestro, D. S. Conklin, and D. Beach. 1999. MaRX: an approach to genetics in mammalian cells. Science 283: 1129–1130.
   PubMedGoogle Scholar
• Hermeking, H., and D. Eick. 1994. Mediation of c-Myc-induced apoptosis by p53. Science 265: 2091–2093.
   PubMed Web of Science ®Google Scholar
• Hollenberg, S. M., P. F. Cheng, and H. Weintraub. 1993. Use of a conditional MyoD transcription factor in studies of MyoD trans-activation and muscle determination. Proc. Natl. Acad. Sci. USA 90: 8028–8032.
   PubMedGoogle Scholar
• Jimenez, G. S., M. Nister, J. M. Stommel, M. Beeche, E. A. Barcarse, X. Q. Zhang, S. O'Gorman, and G. M. Wahl. 2000. A transactivation-deficient mouse model provides insights into Trp53 regulation and function. Nat. Genet. 26: 37–43.
   PubMed Web of Science ®Google Scholar
• Kapoor, M., and G. Lozano. 1998. Functional activation of p53 via phosphorylation following DNA damage by UV but not gamma radiation. Proc. Natl. Acad. Sci. USA 95: 2834–2837.
   PubMed Web of Science ®Google Scholar
• Kastan, M. B., Q. Zhan, W. S. el-Deiry, F. Carrier, T. Jacks, W. V. Walsh, B. S. Plunkett, B. Vogelstein, and A. J. Fornace, Jr. 1992. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71: 587–597.
   PubMed Web of Science ®Google Scholar
• Kern, S. E., K. W. Kinzler, A. Bruskin, D. Jarosz, P. Friedman, C. Prives, and B. Vogelstein. 1991. Identification of p53 as a sequence-specific DNA-binding protein. Science 252: 1708–1711.
   PubMed Web of Science ®Google Scholar
• Lambert, P. F., F. Kashanchi, M. F. Radonovich, R. Shiekhattar, and J. N. Brady. 1998. Phosphorylation of p53 serine 15 increases interaction with CBP. J. Biol. Chem. 273: 33048–33053.
   PubMed Web of Science ®Google Scholar
• Lee, C. W., T. S. Sorensen, N. Shikama, and N. B. La Thangue. 1998. Functional interplay between p53 and E2F through co-activator p300. Oncogene 16: 2695–2710.
   PubMedGoogle Scholar
• Lin, A. W., M. Barradas, J. C. Stone, L. van Aelst, M. Serrano, and S. W. Lowe. 1998. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev. 12: 3008–3019.
   PubMed Web of Science ®Google Scholar
• Lin, A. W., and S. W. Lowe. 2001. Oncogenic ras activates the ARF-p53 pathway to suppress epithelial cell transformation. Proc. Natl. Acad. Sci. USA 98: 5025–5030.
   PubMed Web of Science ®Google Scholar
• Lin, Y., and S. Benchimol. 1995. Cytokines inhibit p53-mediated apoptosis but not p53-mediated G1 arrest. Mol. Cell. Biol. 15: 6045–6054.
   PubMedGoogle Scholar
• Linke, S. P., K. C. Clarkin, A. Di Leonardo, A. Tsou, and G. M. Wahl. 1996. A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev. 10: 934–947.
   PubMed Web of Science ®Google Scholar
• Lowe, S. W., and H. E. Ruley. 1993. Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis. Genes Dev. 7: 535–545.
   PubMed Web of Science ®Google Scholar
• Lowe, S. W., H. E. Ruley, T. Jacks, and D. E. Housman. 1993. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957–967.
   PubMed Web of Science ®Google Scholar
• Lu, H., Y. Taya, M. Ikeda, and A. J. Levine. 1998. Ultraviolet radiation, but not gamma radiation or etoposide-induced DNA damage, results in the phosphorylation of the murine p53 protein at serine-389. Proc. Natl. Acad. Sci. USA 95: 6399–6402.
   PubMed Web of Science ®Google Scholar
• Maltzman, W., and L. Czyzyk. 1984. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol. Cell. Biol. 4: 1689–1694.
   PubMed Web of Science ®Google Scholar
• Michalovitz, D., O. Halevy, and M. Oren. 1990. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell 62: 671–680.
   PubMed Web of Science ®Google Scholar
• Mitsudomi, T., J. Viallet, J. L. Mulshine, R. I. Linnoila, J. D. Minna, and A. F. Gazdar. 1991. Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene 6: 1353–1362.
   PubMed Web of Science ®Google Scholar
• Montes de Oca Luna, R., D. S. Wagner, and G. Lozano. 1995. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378: 203–206.
   PubMed Web of Science ®Google Scholar
• Morgenstern, J. P., and H. Land. 1990. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 18: 3587–3596.
   PubMed Web of Science ®Google Scholar
• Nelson, W. G., and M. B. Kastan. 1994. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol. Cell. Biol. 14: 1815–1823.
   PubMed Web of Science ®Google Scholar
• Nigro, J. M., K. D. Aldape, S. M. Hess, and T. D. Tlsty. 1997. Cellular adhesion regulates p53 protein levels in primary human keratinocytes. Cancer Res. 57: 3635–3639.
   PubMedGoogle Scholar
• Oda, K., H. Arakawa, T. Tanaka, K. Matsuda, C. Tanikawa, T. Mori, H. Nishimori, K. Tamai, T. Tokino, Y. Nakamura, and Y. Taya. 2000. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 102: 849–862.
   PubMed Web of Science ®Google Scholar
• Palmero, I., C. Pantoja, and M. Serrano. 1998. p19ARF links the tumour suppressor p53 to Ras. Nature 395: 125–126.
   PubMed Web of Science ®Google Scholar
• Pearson, M., R. Carbone, C. Sebastiani, M. Cioce, M. Fagioli, S. Saito, Y. Higashimoto, E. Appella, S. Minucci, P. P. Pandolfi, and P. G. Pelicci. 2000. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 406: 207–210.
   PubMed Web of Science ®Google Scholar
• Pomerantz, J., N. Schreiber-Agus, N. J. Liegeois, A. Silverman, L. Alland, L. Chin, J. Potes, K. Chen, I. Orlow, H. W. Lee, C. Cordon-Cardo, and R. A. DePinho. 1998. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92: 713–723.
   PubMed Web of Science ®Google Scholar
• Rainwater, R., D. Parks, M. E. Anderson, P. Tegtmeyer, and K. Mann. 1995. Role of cysteine residues in regulation of p53 function. Mol. Cell. Biol. 15: 3892–3903.
   PubMed Web of Science ®Google Scholar
• Ries, S., C. Biederer, D. Woods, O. Shifman, S. Shirasawa, T. Sasazuki, M. McMahon, M. Oren, and F. McCormick. 2000. Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell 103: 321–330.
   PubMed Web of Science ®Google Scholar
• Rodriguez, M. S., J. M. Desterro, S. Lain, C. A. Midgley, D. P. Lane, and R. T. Hay. 1999. SUMO-1 modification activates the transcriptional response of p53. EMBO J. 18: 6455–6461.
   PubMed Web of Science ®Google Scholar
• Ruggero, D., Z. G. Wang, and P. P. Pandolfi. 2000. The puzzling multiple lives of PML and its role in the genesis of cancer. Bioessays 22: 827–835.
   PubMedGoogle Scholar
• Serrano, M., A. W. Lin, M. E. McCurrach, D. Beach, and S. W. Lowe. 1997. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88: 593–602.
   PubMed Web of Science ®Google Scholar
• Sherr, C. J., and R. A. DePinho. 2000. Cellular senescence: mitotic clock or culture shock? Cell 102: 407–410.
   PubMed Web of Science ®Google Scholar
• Sherr, C. J., and J. D. Weber. 2000. The ARF/p53 pathway. Curr. Opin. Genet. Dev. 10: 94–99.
   PubMed Web of Science ®Google Scholar
• Sionov, R. V., and Y. Haupt. 1999. The cellular response to p53: the decision between life and death. Oncogene 18: 6145–6157.
   PubMed Web of Science ®Google Scholar
• Sugrue, M. M., D. Y. Shin, S. W. Lee, and S. A. Aaronson. 1997. Wild-type p53 triggers a rapid senescence program in human tumor cells lacking functional p53. Proc. Natl. Acad. Sci. USA 94: 9648–9653.
   PubMed Web of Science ®Google Scholar
• Tanaka, N., M. Ishihara, M. S. Lamphier, H. Nozawa, T. Matsuyama, T. W. Mak, S. Aizawa, T. Tokino, M. Oren, and T. Taniguchi. 1996. Cooperation of the tumour suppressors IRF-1 and p53 in response to DNA damage. Nature 382: 816–818.
   PubMed Web of Science ®Google Scholar
• Tao, W., and A. J. Levine. 1999. P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc. Natl. Acad. Sci. USA 96: 6937–6941.
   PubMed Web of Science ®Google Scholar
• Wagner, A. J., J. M. Kokontis, and N. Hay. 1994. Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1. Genes Dev. 8: 2817–2830.
   PubMed Web of Science ®Google Scholar
• Wang, Y., G. Blandino, M. Oren, and D. Givol. 1998. Induced p53 expression in lung cancer cell line promotes cell senescence and differentially modifies the cytotoxicity of anti-cancer drugs. Oncogene 17: 1923–1930.
   PubMed Web of Science ®Google Scholar
• Weber, J. D., L. J. Taylor, M. F. Roussel, C. J. Sherr, and D. Bar-Sagi. 1999. Nucleolar Arf sequesters Mdm2 and activates p53. Nat. Cell Biol. 1: 20–26.
   PubMed Web of Science ®Google Scholar
• Webley, K., J. A. Bond, C. J. Jones, J. P. Blaydes, A. Craig, T. Hupp, and D. Wynford-Thomas. 2000. Posttranslational modifications of p53 in replicative senescence overlapping but distinct from those induced by DNA damage. Mol. Cell. Biol. 20: 2803–2808.
   PubMedGoogle Scholar
• Wu, X., J. H. Bayle, D. Olson, and A. J. Levine. 1993. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7: 1126–1132.
   PubMed Web of Science ®Google Scholar
• Wu, X., and A. J. Levine. 1994. p53 and E2F-1 cooperate to mediate apoptosis. Proc. Natl. Acad. Sci. USA 91: 3602–3606.
   PubMed Web of Science ®Google Scholar
• Yonish-Rouach, E., D. Resnitzky, J. Lotem, L. Sachs, A. Kimchi, and M. Oren. 1991. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352: 345–347.
   PubMed Web of Science ®Google Scholar
• Yuasa, Y., S. K. Srivastava, C. Y. Dunn, J. S. Rhim, E. P. Reddy, and S. A. Aaronson. 1983. Acquisition of transforming properties by alternative point mutations within c-bas/has human proto-oncogene. Nature 303: 775–779.
   PubMed Web of Science ®Google Scholar
• Zhang, Y., Y. Xiong, and W. G. Yarbrough. 1998. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92: 725–734.
   PubMed Web of Science ®Google Scholar
• Zhao, R., K. Gish, M. Murphy, Y. Yin, D. Notterman, W. H. Hoffman, E. Tom, D. H. Mack, and A. J. Levine. 2000. Analysis of p53-regulated gene expression patterns with oligonucleotide arrays. Genes Dev. 14: 981–993.
   PubMedGoogle Scholar
• Zhu, J., D. Woods, M. McMahon, and J. M. Bishop. 1998. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev. 12: 2997–3007.
   PubMed Web of Science ®Google Scholar
• Zindy, F., C. M. Eischen, D. H. Randle, T. Kamijo, J. L. Cleveland, C. J. Sherr, and M. F. Roussel. 1998. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 12: 2424–2433.
   PubMed Web of Science ®Google Scholar